FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3159274329> ?p ?o ?g. }

• W3159274329 abstract "Abstract Background Virtually all metastatic patients with metastatic melanoma who progress after initial treatment with PD-1 or CTLA-4 directed antibodies will die of their disease. Salvage options are urgently needed. It is theoretically attractive to combine immunotherapy with targeted agents in progressing patients with BRAF mutation positive melanoma, but the toxicity of combined treatment has proven challenging. Methods We performed a retrospective analysis of our patient database and identified 23 patients who progressed on initial checkpoint inhibitor treatment, who subsequently had cautious addition of BRAF±MEK inhibitor therapy to continued PD-1 antibody treatment. Results We found an objective response rate of 55% in second line therapy, with a median progression-free survival of 33.4 months and median overall survival of 34.1 months, with 40% of patients in unmaintained remission at over 3 years. Ten of 12 responding patients were able to discont i nue all therapy and continue in unmaintained remission. Toxicity of this approach was generally manageable (21.7% grade 3–5 toxicity). There was 1 early sudden death for unknown reasons in a responding patient. Discussion Our results suggest that 2nd line therapy with PD-1 inhibitors plus BRAF±MEK inhibitors has substantial activity and manageable toxicity. This treatment can induce additional durable complete responses in patients who have progressed on initial immunotherapy. These results suggest further evaluation be performed of sequential PD-1 antibody treatment with cautious addition of targeted therapy in appropriate patients." @default.
• W3159274329 created "2021-05-10" @default.
• W3159274329 creator A5078460149 @default.
• W3159274329 creator A5087752875 @default.
• W3159274329 date "2021-11-07" @default.
• W3159274329 modified "2023-10-14" @default.
• W3159274329 title "Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy" @default.
• W3159274329 cites W1513769484 @default.
• W3159274329 cites W1547515123 @default.
• W3159274329 cites W1994993231 @default.
• W3159274329 cites W2082217156 @default.
• W3159274329 cites W2102382685 @default.
• W3159274329 cites W2105747169 @default.
• W3159274329 cites W2106494998 @default.
• W3159274329 cites W2107484016 @default.
• W3159274329 cites W2114903025 @default.
• W3159274329 cites W2118982164 @default.
• W3159274329 cites W2134267409 @default.
• W3159274329 cites W2137723371 @default.
• W3159274329 cites W2147630681 @default.
• W3159274329 cites W2343457304 @default.
• W3159274329 cites W2560367415 @default.
• W3159274329 cites W2572174216 @default.
• W3159274329 cites W2578528809 @default.
• W3159274329 cites W2603647816 @default.
• W3159274329 cites W2611270905 @default.
• W3159274329 cites W2753432434 @default.
• W3159274329 cites W2779503684 @default.
• W3159274329 cites W2787347138 @default.
• W3159274329 cites W2798102020 @default.
• W3159274329 cites W2887577080 @default.
• W3159274329 cites W2888349826 @default.
• W3159274329 cites W2890978523 @default.
• W3159274329 cites W2913383852 @default.
• W3159274329 cites W2913619761 @default.
• W3159274329 cites W2914864738 @default.
• W3159274329 cites W2934136497 @default.
• W3159274329 cites W2944746103 @default.
• W3159274329 cites W2948155539 @default.
• W3159274329 cites W2955562873 @default.
• W3159274329 cites W2975964438 @default.
• W3159274329 cites W2978943095 @default.
• W3159274329 cites W2982025364 @default.
• W3159274329 cites W2987654547 @default.
• W3159274329 cites W2988644538 @default.
• W3159274329 cites W2999417355 @default.
• W3159274329 cites W3034459487 @default.
• W3159274329 cites W3043661095 @default.
• W3159274329 cites W3043703771 @default.
• W3159274329 cites W3090257754 @default.
• W3159274329 cites W3114356388 @default.
• W3159274329 cites W4293241248 @default.
• W3159274329 doi "https://doi.org/10.1186/s12885-021-08906-1" @default.
• W3159274329 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8573907" @default.
• W3159274329 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34743688" @default.
• W3159274329 hasPublicationYear "2021" @default.
• W3159274329 type Work @default.
• W3159274329 sameAs 3159274329 @default.
• W3159274329 citedByCount "5" @default.
• W3159274329 countsByYear W31592743292022 @default.
• W3159274329 countsByYear W31592743292023 @default.
• W3159274329 crossrefType "journal-article" @default.
• W3159274329 hasAuthorship W3159274329A5078460149 @default.
• W3159274329 hasAuthorship W3159274329A5087752875 @default.
• W3159274329 hasBestOaLocation W31592743291 @default.
• W3159274329 hasConcept C121608353 @default.
• W3159274329 hasConcept C126322002 @default.
• W3159274329 hasConcept C143998085 @default.
• W3159274329 hasConcept C2776694085 @default.
• W3159274329 hasConcept C2776999253 @default.
• W3159274329 hasConcept C2777658100 @default.
• W3159274329 hasConcept C2777701055 @default.
• W3159274329 hasConcept C2780140570 @default.
• W3159274329 hasConcept C2780775027 @default.
• W3159274329 hasConcept C2781230642 @default.
• W3159274329 hasConcept C29730261 @default.
• W3159274329 hasConcept C2994587330 @default.
• W3159274329 hasConcept C502942594 @default.
• W3159274329 hasConcept C71924100 @default.
• W3159274329 hasConceptScore W3159274329C121608353 @default.
• W3159274329 hasConceptScore W3159274329C126322002 @default.
• W3159274329 hasConceptScore W3159274329C143998085 @default.
• W3159274329 hasConceptScore W3159274329C2776694085 @default.
• W3159274329 hasConceptScore W3159274329C2776999253 @default.
• W3159274329 hasConceptScore W3159274329C2777658100 @default.
• W3159274329 hasConceptScore W3159274329C2777701055 @default.
• W3159274329 hasConceptScore W3159274329C2780140570 @default.
• W3159274329 hasConceptScore W3159274329C2780775027 @default.
• W3159274329 hasConceptScore W3159274329C2781230642 @default.
• W3159274329 hasConceptScore W3159274329C29730261 @default.
• W3159274329 hasConceptScore W3159274329C2994587330 @default.
• W3159274329 hasConceptScore W3159274329C502942594 @default.
• W3159274329 hasConceptScore W3159274329C71924100 @default.
• W3159274329 hasIssue "1" @default.
• W3159274329 hasLocation W31592743291 @default.
• W3159274329 hasLocation W31592743292 @default.
• W3159274329 hasLocation W31592743293 @default.
• W3159274329 hasLocation W31592743294 @default.
• W3159274329 hasLocation W31592743295 @default.
• W3159274329 hasLocation W31592743296 @default.

• next